UCB SA - Company Profile

Powered by

All the sales intelligence you need on UCB SA in one solution.

$395 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how UCB SA fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with UCB SA.

Back to companies

UCB SA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

View more

UCB SA (UCB) is a biopharmaceutical company which is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It develops products for the treatment of neurology and immunology-related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Anderlecht, Brussels-Capital Region, Belgium.

 Gain a 360-degree view of UCB SA and make more informed decisions for your business Gain a 360-degree view of UCB SA and make more informed decisions for your business Learn more
Headquarters Belgium
Address Allee De La Recherche, 60, Anderlecht, Bruxelles-Capitale , 1070
Website www.ucb.com
Telephone 32 2 5599999
No of Employees 10,117
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange UCB (EBR)
Revenue (2024) $8.7B 25.8% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 46.3% (2024 vs 2023)
Market Cap* $57.1B
Net Profit Margin (2024) XYZ 16.3% (2024 vs 2023)
* As of and is in US$
View UCB SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

UCB SA premium industry data and analytics

840+

Clinical Trials

Determine UCB SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

470+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for UCB SA’s relevant decision makers and contact details.

290+

Catalyst Calendar

Proactively evaluate UCB SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

160+

Marketed Drugs

Understand UCB SA’s commercialized product portfolio to stay one step ahead of the market.

90+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

90+

Pipeline Drugs

Identify which of UCB SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Sales & Consensus Forecasts

Understand the current and future drug revenue for UCB SA and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across UCB SA, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

3

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for UCB SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

Products and Services

Products Brands
Briviact (brivaracetam):- Epilepsy Cimzia
Bimzelx (bimekizumab):-Plaque psoriasis; Psoriatic arthritis; Axial spondyloarthritis; Hidradenitis suppurativa Briviact
Cimzia (certolizumab pegol):- Ankylosing spondylitis; Axial spondyloarthritis; Crohn’s disease; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Polyarticular juvenile idiopathic arthritis Bimzelx
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand UCB SA portfolio and identify potential areas for collaboration Understand UCB SA portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2026 New Products/Services In June, the company introduced the inaugural UCB Hidradenitis Suppurativa Scholarship Program.
2026 Product Recall In May, the company announced a voluntary recall of 16 lots of CIMZIA (certolizumab pegol) pre-filled syringes in the US.
2026 Corporate Changes/Expansions In May, the company expanded its FASTRAX Canada program into Quebec, Canada.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters UCB SA Roche Holding AG AstraZeneca Plc Novartis AG Sanofi
Headquarters Belgium Switzerland United Kingdom Switzerland France
City Anderlecht Basel Cambridge Basel Paris
State/Province Bruxelles-Capitale Basel-Stadt Cambridgeshire Basel-Stadt Ile-de-France
No. of Employees 10,117 112,774 96,100 75,267 76,493
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Jonathan Peacock Chairman Executive Board 2023 68
Jean-Christophe Tellier Director; Chief Executive Officer Executive Board 2015 67
Sandrine Dufour Chief Financial Officer; Executive Vice President Senior Management 2020 60
Alistair Henry Executive Vice President; Chief Scientific Officer Senior Management 2024 59
Jean-Luc Fleurial Executive Vice President; Chief Human Resources Officer Senior Management 2017 61
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into UCB SA key executives to enhance your sales strategy Gain insight into UCB SA key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?